The main determinants of noninvasive mechanical ventilation (NIV) efficacy and benefit are represented by the type of indication of acute hypoxemic respiratory failure (AHRF) and by patient selection, especially in immunocompromised patients. NIV has been associated with lower rates of endotracheal intubation in patients with acute respiratory failure. NIV is similar to standard oxygen therapy, avoiding endotracheal intubation for recipients of solid organ transplantation and for hematology patients with AHRF.
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Avoiding intubation is a major goal in the management of respiratory failure, particularly in immunosuppressed patients, and especially in recipients of BMT. 3 In this issue of Bone Marrow Transplant, Wermke et al. 4 report on a randomized trial that was conducted to prove the impact of early NIV in patients in the early post-transplant period. The report includes the observation of 526 patients undergoing HSCT in a single center who were monitored for signs of AHRF. Patients with AHRF were enrolled into either treatment arm A (oxygen supply only) or treatment arm B (oxygen þ intermittent NIV).
The authors' hypothesis was that an early interventional strategy using NIV is not associated with improvement in the prognosis of the patients. This is potentially a relevant hypothesis; however, in our view, certain concerns regarding this study must be emphasised as some points that determine a proper assessment of some methodological aspects are important: First, in the strict sense, this is a negative randomized controlled trial (RCT) but with strong signals for a protective effect of NIV, which is obscured by the following: (1) lack of power (reducing mortality from 80 to 50% is too optimistic a perception); (2) diluting a possible preventive effect by including patients who are less ill and do not proceed to 'full' respiratory failure (as you suggest in the letter); and (3) by allowing control patients to receive NIV when their condition is deteriorating (or not responding to oxygen therapy). As such, the results of the trial are equivocal and clearly invoke the need for a new, larger RCT.
Second the cause of AHRF was unclear in most of the patients, with specific results of medical imaging revealing negative or inconclusive broncoalveolar lavage and so on. This concurs with our personal experience: most of the HSCT patients who are referred to our intensive care unit (ICU) with acute renal failure (ARF) have a clinical profile of slowly progressing acute lung injury-acute respiratory distress syndrome, without an identifiable cause or etiology. We think that this lack of an identifiable (and reversible) cause is the main reason for the dismal prognosis, with the only prospect being the chance for a spontaneous 'remission' or 'healing' while providing respiratory support.
The cause of ARF is probably the most important determinant of outcome, and, although the authors did not elucidate the cause of AHRF further, they could delineate some categories (infectious, cardiac failure/fluid overload, unclear (that is, multifactorial cause)), which may provide information about the subgroups of patients who benefit most from a trial on NIV.
Third, tachypnea was quite uncommon in patients suffering from AHRF after HSCT, with only eight patients having a respiratory rate exceeding 25/min. 5 This may explain a subgroup with mild or lower severity enrolled in this study. In the study by Hilbert, 2 the respiratory frequency was found to be higher (35 ± 3).
Although the authors found an improvement in the oxygenation of patients treated with NIV, no information has been provided on adherence and monitoring of dyspnea on a comparison of oxygen therapy with NIV. Hilbert et al. 2 reported that oxygenation effects persist over time in patients with NIV, being significant at 45 min until the end of treatment. The lack of significance at 45 min in patients of this study during the early periods could be related to severe lung disease or to a lower level of pressure applied. The absence of this information does not clarify this important aspect and is a limitation to this study. It is also important to understand the reasons for serious complications arising from endotracheal intubation in the intensive care unit pertaining to NIV intolerance, which may provide an answer for unexplained results.
Fourth, from a methodological point of view, the authors selected a kind of ventilator support, a homecare ventilator, that may have been suboptimal because of the absence of a continuous fraction of inspired oxygen (FiO2), which is a crucial element for adequate oxygenation.
6 They selected the bi-level positive airway pressure mode as the NIV strategy, but they did not explain what volume of FiO2 was used and gave no reason for excluding the continuous positive airway pressure mode. It lacks information on FIO2 during NIV and about the oxygen therapy group, which is another important aspect. They carried out the therapy for a limited period of 30 min every 3 h; it is difficult to envisage a protective effect of 30 min of NIV persisting for several hours.
Finally, how the previous mode of NIV outside the ICU or training education program has been modified for application in the study has also not been described, which may interfere with its implementation and results of at least 5 years of analysis. 7 We believe that further studies on application of NIV outside the ICU should be conducted. Further, the parameters for respiratory failure should be identified early, which would allow for a more focused implementation.
